IMDNA develops gene-expression research assays for focused analysis of biologically selected transcripts, differential-expression studies, pathway profiling, treatment-response research, biomarker verification, and validation of findings generated by RNA sequencing, microarrays, and other transcriptomic approaches.
Research programs can be configured as single-target, multiplex, or multi-panel RT-qPCR workflows. Assay design is built around the biological question, specimen, transcript abundance, RNA quality, reference-gene strategy, and intended analysis rather than a fixed universal gene list.
Measure selected genes and pathway modules with focused RT-qPCR workflows.
Use RT-qPCR to independently investigate candidate transcripts identified by broader transcriptomic studies.
Select and validate reference genes for the actual specimen, experimental condition, and biological contrast.
Profile molecular changes across disease models, perturbations, exposures, dose groups, and time points.
Configure genes, amplicons, controls, normalization, and multiplex structure around the research objective.
RT-qPCR remains one of the most widely used methods for targeted gene-expression research, but reliable interpretation depends on more than detecting amplification. Current MIQE 2.0 guidance emphasizes sample quality, reverse-transcription performance, assay specificity, amplification efficiency, controls, dynamic range, normalization, and transparent data analysis. Expression results can be strongly influenced by preanalytics, RNA integrity, cell composition, reverse-transcription efficiency, reference-gene choice, and analysis method.
Genes should be selected from a defined biological hypothesis, pathway, discovery dataset, or reproducible prior evidence. A targeted expression panel is strongest when every transcript has a clear reason for inclusion.
RNA quantity, integrity, purity, inhibitors, transcript abundance, priming strategy, reverse transcriptase, and reaction conditions can materially affect RT-qPCR measurements. Reverse transcription itself can introduce target-dependent variability.
No housekeeping gene should be assumed to be invariant across all tissues, treatments, diseases, or experimental conditions. Candidate reference genes must be tested for stability in the study context.
MIQE 2.0 emphasizes that Cq values are intermediate measurements and that quantitative interpretation should account for amplification efficiency, target quantity, appropriate normalization, and the dynamic range of each assay.
IMDNA expression assays can be organized as pathway-oriented modules or investigator-selected gene sets rather than a universal “30-gene” configuration.
Investigate cytokine, chemokine, innate-sensing, NF-κB, interferon, and inflammatory-response transcriptional programs.
Study activation, inhibitory, regulatory, T-cell, B-cell, cytotoxic, tolerance, and immune-homeostasis transcriptional pathways.
Profile growth, checkpoint, mitotic, proliferation-associated, and cellular-state gene-expression programs.
Investigate pro-apoptotic, anti-apoptotic, stress-response, and survival-associated transcriptional programs.
Study oxygen-sensing, hypoxia-response, angiogenic, metabolic-adaptation, and stress-associated genes.
Explore redox regulation, ROS-generating pathways, antioxidant responses, and cellular adaptation to oxidative injury.
Investigate genomic-stability, checkpoint, repair, replication-stress, and treatment-associated DNA-damage response pathways.
Study TGF-β-associated, extracellular-matrix, collagen, MMP, fibroblast, and tissue-remodeling transcriptional programs.
Profile selected NK-cell and cytotoxic T-cell effector transcripts in appropriate immune research contexts.
Study energy metabolism, mitochondrial stress, mitophagy, redox, and metabolic-adaptation pathways.
Compare transcript profiles across untreated controls, treatment groups, doses, time points, responder states, and resistant models.
Build investigator-defined gene sets around a disease model, pathway, cell type, pharmacologic perturbation, or discovery result.
The strongest design depends on whether the project begins with a known biological hypothesis, a discovery dataset, or a need for reproducible longitudinal measurements.
Best suited for: focused measurement of a predefined set of transcripts.
Development principle: assay specificity, amplification efficiency, dynamic range, reverse-transcription performance, controls, and normalization must be validated for the intended sample type.
Best suited for: independent targeted follow-up of selected candidates from broad discovery datasets.
Development principle: candidate genes and reference genes should be selected using the actual transcriptomic dataset and then validated by RT-qPCR under the same biological contrasts.
Best suited for: efficient targeted measurement of multiple genes across reproducible research workflows.
Development principle: multiplexing requires demonstration that primer/probe combinations do not materially compromise efficiency, specificity, quantitative range, or low-abundance target performance.
These examples show how a research assay can be structured. They are not fixed signatures and should be adapted to the biological question and specimen.
HPRT1, PPIA, RPLP0, TBP, GAPDH, ACTB, B2M, SDHA and other commonly used housekeeping genes can be useful candidates, but published studies repeatedly show that stability depends on tissue, cell type, disease state, treatment, developmental state, and experimental condition. Reference-gene validation is therefore a core component of assay development.
| Candidate Reference Gene | Potential Use | Critical Scientific Requirement |
|---|---|---|
| HPRT1 | Common candidate in many human gene-expression studies. | Must be evaluated for stability in the actual sample set; it can be unsuitable in some biological contexts. |
| PPIA | Frequently evaluated as a normalization candidate in tissues and cells. | Expression may vary with tissue or experimental condition and must not be assumed invariant. |
| RPLP0 | Ribosomal-related candidate often useful in selected tissues and disease studies. | Suitability is experiment-specific and should be assessed together with other candidates. |
| TBP | Can be stable in selected immune-cell or blood-cell studies. | Performance must be verified under the actual stimulation, disease, or treatment conditions. |
| GAPDH / ACTB | Historically common housekeeping genes. | Neither should be used automatically; both can vary with tissue, metabolism, differentiation, disease, or treatment. |
A defensible expression program should be designed around the intended biological interpretation rather than around Cq values alone.
| Stage | Best-Practice Approach | Scientific Rationale |
|---|---|---|
| 1. Define intended research use | Specify biological question, sample type, experimental groups, treatment, time point, transcript targets, and endpoint. | Determines assay architecture and required analytical performance. |
| 2. Assess RNA quality & preanalytics | Document collection, stabilization, storage, extraction, RNA quantity/quality, inhibitors, and DNase treatment where appropriate. | Preanalytical variation can become indistinguishable from biological expression differences. |
| 3. Design transcript-specific assays | Define transcript/isoform target, amplicon location, primer/probe specificity, splice-junction strategy where relevant, and expected expression range. | Gene-level and transcript-level questions are not always equivalent. |
| 4. Validate reverse transcription | Control RNA input, priming strategy, reverse transcriptase, reaction conditions, and no-RT controls. | RT yield and specificity can vary substantially among targets and samples. |
| 5. Establish PCR performance | Evaluate specificity, efficiency, linearity, dynamic range, LOD/LOQ where appropriate, repeatability, and robustness. | Quantitative interpretation requires known assay behavior rather than assuming ideal amplification. |
| 6. Validate reference genes | Screen multiple candidate genes across the actual biological conditions and use tools such as geNorm, NormFinder, or equivalent statistical approaches. | Normalization can change the apparent direction or magnitude of biological effects. |
| 7. Convert Cq to interpretable quantities | Use efficiency-aware target quantities and an explicit normalization strategy rather than treating raw Cq, ΔCq, or ΔΔCq values as universally comparable. | MIQE 2.0 emphasizes that Cq is an intermediate measurement influenced by efficiency and thresholding. |
| 8. Verify biologically & independently | Use biological replication, appropriate statistical analysis, orthogonal evidence where relevant, and independent cohorts/sample sets for signatures. | Analytical validity does not by itself establish biological generalizability. |
Gene-expression research requires careful separation of transcript abundance, protein abundance, cell composition, biological function, and clinical meaning.
Small technical differences in RNA quality, reverse transcription, amplification efficiency, reference-gene selection, or thresholding can create or obscure apparent expression differences.
Therefore: IMDNA positions these assays for mechanistic, biomarker, pathway, transcript-validation, and translational research—not as universal diagnostic or disease-specific expression signatures.
A rigorous gene-expression workflow connects biological design, RNA quality, transcript-specific assay development, reference-gene validation, efficiency-aware quantification, and biological verification.
The updated MIQE framework places substantial emphasis on the entire workflow—from sample handling and reverse transcription to quantitative analysis and reporting.
Control collection, stabilization, extraction, RNA quantity/quality, genomic-DNA contamination, storage, and freeze-thaw exposure.
Define priming method, RNA input, RT enzyme, reaction conditions, cDNA handling, and no-RT controls.
Evaluate primer/probe specificity, amplicon identity, PCR efficiency, linearity, dynamic range, and robustness.
Use no-template, no-RT, positive, process, and other study-appropriate controls to distinguish technical artifacts from biological signal.
Evaluate several candidate reference genes and use a normalization factor based on validated stable genes where appropriate.
Use efficiency-aware quantities, transparent normalization, biological replicates, appropriate statistics, and full reporting of experimental details.
Gene-expression research rarely fits a universal panel. IMDNA can develop focused RT-qPCR research solutions around investigator-selected genes, discovery datasets, biological pathways, specimen types, longitudinal studies, and experimental objectives.
Whether your work focuses on differential gene expression, pathway biology, biomarker verification, RNA-seq follow-up, treatment response, immune signaling, inflammation, cell proliferation, apoptosis, hypoxia, oxidative stress, DNA repair, fibrosis, cytotoxicity, or investigator-defined signatures, IMDNA can develop a targeted RT-qPCR research workflow around the transcripts and biological question that matter to your study.